Socarrás-Ferrer BB, del Valle-Pérez LO, de la Cuétara-Bernal K, Marsán-Súarez V, Sánchez-Segura M, Macías-Abraham C

Idioma: Español
Referencias bibliográficas: 27
Paginas: 16-23
Archivo PDF: 99.30 Kb.

RESUMEN

Se describen los aspectos más relevantes de las células madre mesenquimales que incluyen su plasticidad hacia diversos linajes celulares, como condrocitos, osteocitos y adipositos, entre otros. Dichas células se pueden obtener principalmente de médula ósea, sangre de cordón umbilical y tejido adiposo, de donde se han logrado establecer cultivos que permiten estudiar sus propiedades funcionales y fenotípicas. Estas expresan antígenos CD73, CD90 y CD105 en ausencia de antígenos hematopoyéticos CD34 y CD45, así como diferentes receptores para citocinas y moléculas de adhesión. Futuras investigaciones permitirán conocer diversos aspectos biológicos de estas células, de importancia en su utilización en la medicina regenerativa como medida terapéutica para solucionar una amplia variedad de enfermedades.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Beyer N, Da Silva L. Mesenchymal stem cells: Isolation in vitro, expansion and characterization. Handb Exp Pharmacol. 2006;(174):249-82. PMID 16370331.

2. Gnecchi M, Melo LG. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol. 2009;482:281-94.

3. Rodríguez V. Células madre: Conceptos generales y perspectivas de investigación. Universitas Scientiarum. 2005 Ene-Jun;10(1):5-14.

4. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968 Mar;6(2):230-47. PMID 5654088.

5. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. CellTissueKinet. 1970 Oct;3(4):393-403. PMID 5523063.

6. Friedenstein AJ, Ivanov-Smolenski AA, Chajlakjan RK, Gorskaya UF, Kuralesova AI, Latzinik NW, et al. Origin of bone marrow stromal machanocytes in radiochimeras and heterotopic transplants. Exp Hematol. 1978 May;6(5):440-4. PMID 350596.

7. Owen M, Friedenstein AJ. Stromal stem cells: marrow derived osteogenic precursors. Ciba Found Symp. 1988;136:42-60. PMID 3068016.

8. Jones R, Lebkowski J, McNiece I. Stem cells. Biol Blood Marrow Transplant. 2010 Jan;16(Suppl 1):S115-S118. PMCID: PMC 3086546.

9. Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, et al. Adult human fi broblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol. 2007 Aug;179(3):1595-1604.

10. Pittenger MF, Mackay AM, Bewck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal cells. Science 1999 Apr;8(5411):143:7. PMID 10102814.

11. Tramain N, Korkko J, Ibberson D, Kopen GC, Di Girolamo C, Phinney DG. MicroSage analysis of 2353 expressed genes in a single cell-derived colony undifferentiated human mesenchymal stem cells reveals mRNAs of multiple cell lineages. Stem Cells. 2001 Sep;19(5):408-18. DOI: 10.1634/stemcells. 19-5-408.

12. Prockop DJ, Sekiya I, Colter DC. Isolation and characterization of rapidly self- renewing stem cells from cultures of human stromal cells. Cytotherapy. 2001;3(5):393-6.

13. Jewett A, Arasteh A, Tseng HC, Behel A, Arasteh H, Yang W, et al. Strategies to rescue mesenchymal stem cells(MSCs) and dental pulp stem cells(DPSCs) from NK cell mediated cytotoxicity. Plos One. 2010 Mar;5(3):e9874. PMID 20360990.

14. Alongi DJ, Yamaza T, Song Y, Fouad AF, Romberg EE, Shi S, et al. Stem/progenitor cells from inflamed human dental pulp retain tissue regeneration potential. Regen Med. 2010 Jul;5(4):617-31.

15. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. StemCells. 2006 May;24(5):1294-1301. PMID 16410387.

16. Krampera M, Passini A, Pizzolo G, Cosmi L, Romagni S, Annunziato F. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol. 2006 Aug;6(4):435-41. PMID 16777484.

17. Ren G, Zhao X, Zhang L, Zhang J, L Huillier A, Ling W, et al. Inflammatorycytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 inmesenchymal stem cells are critical for immunosuppresion. J Immunol. 2010 Mar;184(5):2321-28. PMID 20130212.

18. Zisa D, Shabbir A, Mastri M, Suzuki G, Techung L. Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells. Am J Physiol Regul Integr Comp Physiol. 2009 Nov;297(5):R1503-15. PMID 19759338.

19. Macías C, del Valle L, Hernández P, Ballester J.Características fenotípicas y funcionales de las células madre mesenquimales y endoteliales. Rev Cubana Hematol Inmunol Hemoter. 2010 Dic;26(4):256-75.

20. Ghannam S, Bouffi C, Djouad F, Jorgensen CH, Noël D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther. 2010 Mar 15;1(1):2.

21. Hamou C, Chang EI, Grogan R. Mesenchymal stem cells can participate in ischemic neovascularization. PlastReconstr Surg. 2009 Feb;123(Suppl 2):45S-55S. PMID 19182663.

22. Wen Z, Zheng S, Zhou C, Wang J, Wang T. Repair mechanisms of bone marrowmesenchymal stem cells in myocardial infarction. J Cell Mol Med. 2011 May;15(5):1032-43. doi: 10.1111/j.1582-4934.2010.01255.x.

23. Sorrell JM, Caplan AI. Topical delivery of mesenchymal stem cells and their function in wounds. StemCell Res Ther. 2010 Sep;1(4):30. PMID: 20863417.

24. Yi T, Song SU.Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res. 2012 Feb;35(2):213-21.

25. Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymalstem cell therapies. Hum Gene Ther. 2010 Dec;21(12):1641-55.

26. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymalstem cell effects on T-cell effector pathways. Stem Cell Res Ther. 2011 Aug 11;2(4):34.

27. Rankin S. Mesenchymal stem cells. Thorax. 2012 Jun;67(6):565-6.